Reviews: 2016 Medicinal Chemistry Reviews

Ref. n°: REV2016

Volume : 51
Editor-In-Chief : Manoj C. Desai

Medicinal Chemistry Reviews is an outstanding 600 page volume providing timely and critical reviews of important topics in medicinal chemistry. It is provided free of charge to MEDI members in electronic format. Members can also order a print copy, for the cost of printing, shipping and handling

Table of contents

Chapter 1Lessons From Decades of R&D Management
Chapter 2Recent Developments in Neuropeptide S Receptor (NPSR) Research
Chapter 3Metabotropic Glutamate Receptors at Thirty: New Insights From Chemical Tools Enabling Mechanistic Understanding
Chapter 4Small-Molecule Selective PPAR-gamma Modulators
Chapter 5Nonpeptide AT2 Receptor Agonists
Chapter 6Recent Developments in Melanin-Concentrating Hormone Receptor 1 Antagonists
Chapter 7Targeting Necroptosis for Therapeutic Intervention in Inflammatory Diseases
Chapter 8Recent Advances in the Discovery and Development of Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists
Chapter 9Small-Molecule Modulators of Protein Arginine Deaminases (PAD)
Chapter 10Estrogen Receptor Degraders for the Treatment of ER-positive Breast Cancer
Chapter 11Small-Molecule Modulators of Keap1-Nrf2
Chapter 12Small-Molecule Modulators Targeting the Unfolded Protein Response Sensor IRE1-alpha
Chapter 13Approaches to Eradicate HIV Infection
Chapter 14Therapeutics for Treatment of Ebola and Other Filovirus Infections
Chapter 15Polymyxins Targeting the Outer Membrane of Gram-Negative Bacteria
Chapter 16Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease
Chapter 17Targeting beta-Amyloid and Tau Protein Oligomers and Aggregates as a Novel Approach to the Treatment of Alzheimer's Disease
Chapter 18Development of VEGFR Inhibitors as Antiangiogenic Agents
Chapter 19Recent Developments in Chiral Phosphorothioate Oligonucleotides
Chapter 20Boron in Medicinal Chemistry
Chapter 21Protein Degraders: Moving Towards Therapeutically Viable Agents
Chapter 22Case History: The Discovery of the First Hepatitis C Virus NS5A Replication Complex Inhibitor Daclatasvir (Daklinza™)
Chapter 23Case History: Vorapaxar (Zontivity®): A First-In-Clas Protease-Activated Receptor-1 (PAR-1) Antagonist Antiplatelet Agent
Chapter 24New Chemical Entities Entering Phase III Trials in 2015
Chapter 25To Market, To Market--2015